Bengal Physician Journal

Register      Login

VOLUME 6 , ISSUE 3 ( September-December, 2019 ) > List of Articles

EDITORIAL

Coronavirus Disease-2019: An Overview and Update

Agnibha Maiti, Anup K Bhattacharya

Citation Information : Maiti A, Bhattacharya AK. Coronavirus Disease-2019: An Overview and Update. Bengal Physician Journal 2019; 6 (3):45-47.

DOI: 10.5005/jp-journals-10070-6126

License: CC BY-NC 4.0

Published Online: 03-08-2020

Copyright Statement:  Copyright © 2019; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract


PDF Share
  1. Van Dreamland N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382(16):1564–1567. DOI: 10.1056/NEJMc2004973.
  2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with the 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5.
  3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395(10223):507–513. DOI: 10.1016/S0140-6736(20)30211-7.
  4. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019(COVID-19)—United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69(12): 343–346. DOI: 10.15585/mmwr.mm6912e2.
  5. Chan JFW, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with 2019 novel coronavirus indicating person to person transmission: a study of a family cluster. Lancet 2020;395(10223):514–523. DOI: 10.1016/S0140-6736(20)30154-9.
  6. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11(1):222. DOI: 10.1038/s41467-019-13940-6.
  7. Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proof reading exoribonuclease. mBio 2018;9(2):e00221. DOI: 10.1128/mBio.00221-18.
  8. Harrison C. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol 2020;38(4):379–381. DOI: 10.1038/d41587-020-00003-1.
  9. Jin YH, Cai L, Cheng Z-S, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 2020;7(1):4. DOI: 10.1186/s40779-020-0233-6.
  10. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;382(19):1787–1799. DOI: 10.1056/NEJMoa2001282.
  11. Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019(COVID-19). Crit Care Med 2020;48(6):e440–e469. DOI: 10.1097/CCM.0000000000004363.
  12. Clinical Pharmacology powered by Clinical Key: Sarilumab. Clinical Key website. Accessed April16, 2020. https://www. clinicalkey.com/#!/content/drug–monograph/6-s2.0-4949.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.